# Japan's GLP-1 Treatment Cap: Weight Regain After a Mandated Stop | Buy This GLP

Under Japan's GLP-1 treatment cap, 21 of 22 patients regained weight within two months of the mandated stop, and mean change went from -14.4% to -7.0% by month 22.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/the-rule-said-stop-and-ninety-five-percent-regained
Updated: 2026-11-14
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Japan's GLP-1 Treatment Cap: Weight Regain After a Mandated Stop

In a Japanese cohort studied under time-limited treatment rules, 21 of 22 patients with two-month follow-up regained weight after the mandated stop.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Weight change against month −6, when the rule starts · 0% · start · -14.4% · cap · -7% · washout · At six months after stopping, only 12 had follow-up data.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   The Japanese guideline described in the study required six months of lifestyle intervention before reimbursed treatment and a break after the treatment cap.
-   The prospective study enrolled 104 patients. Thirty had weight data at month 16, and fewer had measurements after stopping.
-   After the mandated stop, 95% (21 of 22) had regained by two months and 83% (10 of 12) by six months.
-   The reported mean weight change was -14.4% at month 16 and -7.0% at month 22, when only 12 patients had follow-up data.

The [guide to GLP-1 prepayment](https://buythisglp.com/research/should-you-prepay-for-a-glp1) explains why the duration of a payment commitment can differ from the duration of treatment. In this small Japanese cohort, a policy set the stopping point [\[1\]](https://buythisglp.com/research/the-rule-said-stop-and-ninety-five-percent-regained#ref-1). Much of the other evidence comes from randomized withdrawal trials or databases that capture people who stopped for different reasons.

During treatment, mean weight change reached a partial plateau across months 10 to 14 at -16.3%, -16.1% and -15.5%, and stood at -16.0% at the month-16 endpoint. Then the cap took effect. Of the patients followed past it, 21 of 22 had regained weight within two months and 10 of 12 within six.

Print the fractions, because the denominators are small

Twenty-two patients, then twelve. This is a 104-person prospective cohort in one program, not a national dataset, and the percentages attached to those fractions carry exactly as much weight as fractions that size deserve. What they show is direction and speed, not a precise rate — the same caution this desk applied to the pooled figures in [the cessation meta-analysis](https://buythisglp.com/research/the-drug-that-works-best-costs-the-most-to-stop).

Relative to the baseline six months before treatment, the study reported mean changes of −14.4% at month 16 and −7.0% at month 22. Follow-up at month 22 included 12 patients. The authors offer this as a basis for examining whether a mandated stop is compatible with obesity being a chronic condition, which is a careful way of putting a pointed question.

The mandated waiting period produced its own finding. During the required six-month lifestyle phase before any drug was allowed, the post-surgery rescue cohort gained weight (+2.28 kg on average, with 69% gaining) while the primary cohort stayed roughly stable (-0.65 kg, p = 0.004). The groups differed in treatment history. The separate guide to [GLP-1 prior authorization](https://buythisglp.com/research/how-long-does-prior-authorization-take-for-a-glp1) describes the delays reported by patients seeking coverage in the United States.

For a self-pay buyer in a market with no such rule, the transferable point is about planning rather than policy. A fixed-term plan or prepaid supply can end before you have a plan for continuing care. Discuss continuity with your prescriber before committing to a term. Pricing a course as a finite purchase and pricing it as an ongoing one are different decisions, as [why falling prices and annual plans do not mix](https://buythisglp.com/research/glp1-falling-prices-vs-annual-plans) sets out.

## Frequently asked

What happened after the mandated stop?

Of the patients followed past it, 21 of 22 had regained weight within two months and 10 of 12 within six. Mean change against the start went from -14.4% at month 16 to -7.0% at month 22.

How large was the study?

104 patients prospectively followed in one program, with 30 at the month-16 treatment endpoint and 22 and 12 at the two post-cessation checks. The fractions are small and the percentages should be read accordingly.

Did the required lifestyle phase help?

Not for everyone. The post-surgery rescue cohort gained an average 2.28 kg during it, with 69% gaining, while the primary cohort stayed roughly stable.

## Sources

1.  \[1\] Inamine S, Uesato Y (2026). GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain Diabetes, Obesity and Metabolism. [PMID 42552238](https://pubmed.ncbi.nlm.nih.gov/42552238/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
